Enhanced Probiotic-Based Antiviral Systems
Legal Citation
Summary of the Inventive Concept
The invention relates to improved antiviral methods and compositions incorporating probiotic bacterial molecules, enhancing efficacy, safety, and bioavailability through strategic combinations, modifications, and personalized approaches.
Background and Problem Solved
The original patent disclosed the use of probiotic bacterial molecules for antiviral treatment, but limitations included potential toxicity, variable efficacy, and limited bioavailability. The new inventive concept addresses these limitations by introducing novel combinations, modifications, and personalized approaches to enhance the antiviral activity of probiotic bacterial molecules.
Detailed Description of the Inventive Concept
The inventive concept comprises four primary aspects: (1) a system combining probiotic bacterial molecules with virus-targeting peptides to enhance efficacy; (2) a method for conjugating probiotic bacterial molecules to virus-binding ligands to increase their affinity for the virus; (3) a composition featuring probiotic bacterial molecules and virus-inhibiting small molecules to enhance bioavailability; and (4) a method for modifying probiotic bacterial molecules to reduce toxicity. Additionally, a system for personalized antiviral treatment is disclosed, comprising a library of probiotic bacterial molecules tailored to specific virus strains.
Novelty and Inventive Step
The new claims introduce novel combinations, modifications, and personalized approaches that significantly improve the antiviral activity, safety, and bioavailability of probiotic bacterial molecules, distinguishing them from the original patent's disclosure.
Alternative Embodiments and Variations
Alternative embodiments may include varying the type and ratio of probiotic bacterial molecules, using different virus-targeting peptides or ligands, and incorporating additional antiviral agents. Variations may also include adapting the inventive concept for different virus strains, administration routes, or patient populations.
Potential Commercial Applications and Market
The enhanced probiotic-based antiviral systems have significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of infectious disease treatment and prevention. Target markets may include hospitals, clinics, and research institutions, as well as consumers seeking alternative antiviral therapies.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Microbiology, virology, and probiotic therapeutic interventions, with expertise in bacterial molecular interactions and antiviral strategies
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in microbiology or biotechnology, familiar with probiotic bacterial strains, viral interaction mechanisms, and molecular modification techniques
Obviousness Rationale
A person skilled in the art would recognize that the PTD's variations represent predictable extensions of the source patent's core concept of using probiotic bacterial molecules for antiviral treatment. The disclosed modifications involve standard molecular engineering techniques and combinatorial approaches commonly employed in therapeutic development. The systematic enhancement of probiotic molecular interactions with viruses represents an expected progression of the original patent's foundational research.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,581 |
|---|---|
| Title | Antiviral methods and compositions comprising probiotic bacterial molecules |
| Assignee(s) | MICROSINTESIS INC. |